Leiomyosarcoma

In a video interview, Sandra D’Angelo, MD, talked about a study of cabozantinib and temozolomide in patients with leiomyosarcoma and other soft tissue sarcomas, which was presented at the Connective Tissue Oncology Society Annual Meeting.

IACS-6274, a selective glutaminase-1 inhibitor, appeared safe and demonstrated antitumor activity among patients with biomarker-selected advanced solid tumors, according to phase 1 study results presented at the virtual ASCO Annual Meeting.

The FDA granted fast track and orphan drug designations to PTC596 for treatment of leiomyosarcoma, according to the agent’s manufacturer.

Doxorubicin in combination with trabectedin appeared to be an effective and safe first-line therapy for metastatic leiomyosarcoma, according to results of the phase 2 LMS-02 study presented during the ASCO20 Virtual Scientific Program.